Background

This study targets unresectable or metastatic skin cancers that occur in kidney transplant recipients. The combination of immunosuppressants and immune checkpoint inhibitors is expected to overcome the limitations of existing therapies. Because kidney transplant patients are in an immunosuppressed state, cancer treatment options have been limited, necessitating a novel approach.

Study Design

The trial employs a combined Phase 1/2 design, administering nivolumab (an immune checkpoint inhibitor) and ipilimumab (a CTLA‑4 inhibitor) together with sirolimus (an immunosuppressant) and prednisone (a corticosteroid). The primary objective is safety and dose exploration, while the secondary objectives include tumor response rate and preservation of renal function. Eligible participants are adult patients diagnosed with skin cancer after kidney transplantation, with enrollment commencing in July 2024.

Expected Benefits

Immune checkpoint inhibitors activate T cells to target tumor cells, while sirolimus and prednisone protect the transplanted kidney. The hypothesis is that concurrent use of these agents can balance tumor control with graft preservation. If successful, this approach could demonstrate an effective anticancer treatment model even within an immunosuppressed environment.

Market and Clinical Significance

Currently, immunotherapy for cancer in immunosuppressed patients is limited and data are scarce. Positive outcomes from this study could establish a new therapeutic paradigm applicable not only to kidney transplant recipients but also to other organ transplant populations. Moreover, the findings may influence the development of regulatory guidance on combination strategies involving immune checkpoint inhibitors and immunosuppressants.

Risks and Outlook

Immune checkpoint inhibitors carry a risk of precipitating graft rejection, making safety profiling a critical issue. Managing adverse events associated with the combination therapy may be challenging. The safety results from early data will determine whether the program proceeds to an expanded Phase 3.